We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
+24.07%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$163M
AUM Growth
–
Cap. Flow
+$196M
Cap. Flow
% of AUM
120.52%
Top 10 Holdings %
Top 10 Hldgs %
40.87%
Holding
62
New
62
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$9.4M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$5.09M |
| 3 |
Biogen
BIIB
|
+$4.14M |
| 4 |
SPNC
Spectranetics Corp
SPNC
|
+$3.75M |
| 5 |
Accuray
ARAY
|
+$3.49M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 50.1% |
| 2 | Technology | 0.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NSPH
51
DELISTED
NANOSPHERE INC. COM NEW
NSPH
| $916K | 0.56% |
+20,000
| New | +$837K |
|
|
ARIA
52
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $887K | 0.55% |
+130,000
| New | +$702K |
|
|
ELGX
53
DELISTED
Endologix Inc
ELGX
| $872K | 0.54% |
+5,000
| New | +$859K |
|
54
Agilent Technologies
A
$37.1B
| $858K | 0.53% |
+20,970
| New | +$797K |
|
|
HZNP
55
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $762K | 0.47% |
+100,000
| New | +$539K |
|
|
DVAX
56
DELISTED
Dynavax Technologies
DVAX
| $686K | 0.42% |
+35,000
| New | +$512K |
|
|
ISEE
57
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $647K | 0.4% |
+20,000
| New | +$593K |
|
|
ASRT
58
DELISTED
Assertio
ASRT
| $529K | 0.33% |
+833
| New | +$407K |
|
|
CHTP
59
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
| $444K | 0.27% |
+100,000
| New | +$338K |
|
|
CPRX
60
DELISTED
Catalyst Pharmaceutical
CPRX
| $341K | 0.21% |
+175,000
| New | +$354K |
|
|
WINT
61
DELISTED
Windtree Therapeutics Inc
WINT
| $225K | 0.14% |
+7,143
| New | +$223K |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q4 2013 Portfolio in Review
Q4 2013 is the first quarter with a 13F filing on record for Ghost Tree Capital, which disclosed 62 positions worth $163M. Its ten largest holdings account for 41% of the portfolio.
Its largest position is Gilead Sciences: 135,000 shares worth $10.1M.
By sector, the portfolio is most concentrated in Healthcare at 50% of assets, followed by Technology.
- Ghost Tree Capital's largest Q4 2013 buy was Gilead Sciences: 135,000 shares worth $10.1M.
- Ghost Tree Capital's ten largest holdings make up 41% of its $163M portfolio in Q4 2013.
- Ghost Tree Capital disclosed 62 positions in Q4 2013, its first 13F filing on record.
Based on Ghost Tree Capital's 13F filing for Q4 2013, filed 14 Feb 2014.